Prostate cancer screening: guidelines review and laboratory issues

Area of Science:

• Urology
• Laboratory Medicine
• Evidence-Based Medicine

Background:

• Prostate-specific antigen (PSA) is a key biomarker for early prostate cancer (PCa) detection.
• Clinical practice guidelines (CPGs) aim to integrate evidence into practice, especially for controversial PCa screening.
• Divergent guidelines exist, and opportunistic screening is not advised.

Purpose of the Study:

• To systematically review clinical practice guidelines (CPGs) for prostate cancer (PCa) screening using PSA.
• To evaluate the inclusion and consideration of laboratory-specific issues within these guidelines.

Main Methods:

• A systematic review of CPGs for PSA-based PCa screening published since 2008 was conducted.
• Twenty-two updated CPGs were assessed using a checklist for laboratory factors (pre-analytical, analytical, post-analytical).
• Guideline quality was evaluated based on evidence grading and algorithm clarity.

Main Results:

• Only 59% of guidelines graded recommendations by evidence level, and 18% provided clear algorithms.
• Laboratory medicine specialists were involved in only 9% of reviewed guidelines.
• Laboratory issues were frequently omitted; only two guidelines considered WHO standards for PSA testing.

Conclusions:

• The quality of PCa early detection guidelines can be significantly enhanced.
• Greater consideration of laboratory issues, including pre-analytical, analytical, and post-analytical factors, is essential for guideline development.
• Incorporating expertise from laboratory medicine specialists and addressing standardization is crucial for improving PCa screening guidelines.